BDRX - What's Going On With Rare/Orphan Disease Focused-Biodexa Pharmaceuticals Stock Friday? | Benzinga
Friday, Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) announced an R&D update, including topline clinical trial results of a recently completed Phase 1 study of MTX110 in patients with diffuse midline glioma (DMG).
In an investigator-initiated study conducted by Columbia University Irving Medical Center, patients newly diagnosed with DMG were administered MTX110 via convection-enhanced delivery (CED) using a subcutaneous pump connected to a catheter directly implanted into the pons in a 3+3 dose-escalating design.
Nine patients were treated in the study (30 M group, n=3; 60 ...